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Simple Summary: Equine atypical myopathy is a muscular disease caused by a plant intoxication, 
which seems to affect only certain horses sharing a pasture, and the role of the intestinal bacteria 
(microbiota) in this selective impairment is still poorly understood. The aim of this study was to 
describe and compare fecal microbiota of horses suffering from atypical myopathy and healthy co-
grazers. We concluded that fecal microbiota of horses suffering from atypical myopathy is different 
from their co-grazers and changes are more severe in horses that do not survive the disease. Under-
standing those changes may help in developing therapeutic and/or preventive strategies for horses 
at risk for atypical myopathy. 
Abstract: Equine atypical myopathy (AM) is caused by hypoglycin A (HGA) and methylenecyclo-
propylglycine (MCPG) intoxication resulting from the ingestion of seeds or seedlings of some Acer tree 
species. Interestingly, not all horses pasturing in the same toxic environment develop signs of the dis-
ease. In other species, it has been shown that the intestinal microbiota has an impact on digestion, 
metabolism, immune stimulation and protection from disease. The objective of this study was to char-
acterize and compare fecal microbiota of horses suffering from AM and healthy co-grazers. Further-
more, potential differences in fecal microbiota regarding the outcome of diseased animals were as-
sessed. This prospective observational study included 59 horses with AM (29 survivors and 30 non-
survivors) referred to three Belgian equine hospitals and 26 clinically healthy co-grazers simultane-
ously sharing contaminated pastures during spring and autumn outbreak periods. Fresh fecal samples 
(rectal or within 30min of defecation) were obtained from all horses and bacterial taxonomy profiling 
obtained by 16S amplicon sequencing was used to identify differentially distributed bacterial taxa be-
tween AM-affected horses and healthy co-grazers. Fecal microbial diversity and evenness were signif-
icantly (p < 0.001) higher in AM-affected horses as compared with their non-affected co-grazers. The 
relative abundance of families Ruminococcaceae, Christensenellaceae and Akkermansiaceae were 
higher (p ≤ 0.001) whereas those of the Lachnospiraceae (p = 0.0053), Bacteroidales (p < 0.0001) and 
Clostridiales (p = 0.0402) were lower in horses with AM, especially in those with a poor prognosis. 
While significant shifts were observed, it is still unclear whether they result from the disease or might 
be involved in the onset of disease pathogenesis. 
Keywords: equine; fecal; intestinal; microbiome; rhabdomyolysis; intoxication; hypoglycin A; 
MCPA-CoA; Ruminococcaceae; Lachnospiraceae 
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Outbreaks of equine atypical myopathy (AM) have occurred recurrently in Europe 
since the mid-1990s with more than 2500 cases reported in the last 10 years, mostly from 
central European countries [1,2]. The disease typically affects horses kept on pasture dur-
ing spring/autumn, causing a non-exercise-induced acute rhabdomyolytic syndrome, af-
fecting mainly postural and respiratory muscles and myocardium [2,3]. Clinical disease 
has been associated with hypoglycin A (HGA) intoxication resulting from the ingestion of 
seeds or seedlings of some Acer tree species [4] in Europe, mainly Acer pseudoplatanus (syc-
amore maple) [5]. Recently, it has been shown that methylenecyclopropylglycine (MCPG) 
is also involved in the development of the disease [6]. The clinical picture is characterized 
by the sudden onset of stiffness, muscular weakness, tachycardia and myoglobinuria, pro-
gressing in many cases to recumbency, respiratory difficulties and death [7,8] Despite the 
discovery of its etiology, there is still no cure for AM and symptomatic therapy is often 
unsuccessful [7–9]. Horses and ponies of any age and breed can be affected, and the re-
ported mortality rate ranges from 43% to 97% [7,10].  
It is the general consensus that intestinal absorption of the protoxins HGA and MCPG 
and their subsequent transformation to toxic metabolites are needed to develop AM, lead-
ing to rhabdomyolysis and, in many cases, even death [11]. Interestingly, and for a reason 
still unknown, not all horses pasturing in the same contaminated environment develop 
clinical signs of the disease. Published data show that HGA can be detected in the blood 
of clinically healthy horses pasturing in at-risk fields [5,12]. Although incidence of clinical 
disease has been linked to specific factors such as age, body condition, feeding and pasture 
management, the exact reason protecting certain horses from developing clinical signs 
remains largely unknown [5,12]. 
Studies in humans and animals have shown that intestinal microbiota has an impact 
on digestion, metabolism, immune stimulation and protection from pathogens and dis-
ease [13–15]. Research in human medicine increasingly confirms a link between dysbiosis 
of the gut microbiota and the pathogenesis not only of intestinal, but also of extra-intesti-
nal, diseases [16]. Similarly, when compared with healthy or control horses, differences in 
the intestinal microbiome have been confirmed for various common equine illnesses, such 
as equine metabolic syndrome, carbohydrate-induced laminitis, colic, colitis and equine 
grass sickness. However, the significance of these findings is yet unclear [17–22]. To date, 
no published studies have investigated the potential role of intestinal microbiota in equine 
AM.  
A wide range of bacteria, including gut microbiota fermenters, are able to metabolize 
peptides and amino acids to use them for protein synthesis or the generation of metabolic 
energy [23,24]. Bacteria may also synthesize amino acids required for protein biosynthesis, 
creating a bilateral exchange between the gut microbiota and the host [25]. Branched-chain 
amino acids are metabolized in humans and in bacteria through the combined action of 
two enzymes, branched-chain amino acid aminotransferase (BCAT) and branched-chain 
oxoacid dehydrogenase (BCAD). Metabolism of MCPG and HGA to their active metabo-
lites MCPF-CoA and MCPA-CoA is accomplished by the same two-step enzymatic system 
[24,26]. Specific intestinal bacteria containing the aforementioned enzymes could poten-
tially contribute to the way HGA and MCPG are absorbed or metabolized in horses graz-
ing contaminated pastures. 
Our research hypothesis was that horses suffering from AM would have a different 
intestinal microbiota compared to their asymptomatic co-grazers. Horses showing clinical 
signs of AM could have a specific intestinal microbiome that contributes to or protects 
them from the development of disease. Decoding pathways of intoxication and/or identi-
fying protective mechanisms against developing clinical disease could help in improving 
prevention and treatment of this devastating pathology. The objective of this study was 
to characterize and compare fecal microbiota of horses with AM and their healthy co-
grazers. Furthermore, potential differences in fecal microbiota regarding the outcome of 
diseased animals were assessed.  
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2. Materials and Methods  
2.1. Study Design and Sample Collection  
A prospective clinical study was conducted from autumn 2016 till spring 2019. The 
studied population included horses diagnosed with AM in three Belgian equine referral 
hospitals (i.e., Clinique Vétérinaire Universitaire de Liège, Faculty of Veterinary Medicine 
Ghent University, Dierenkliniek de Morette) during the study period. Whenever it was 
possible, for each sick horse, one or more healthy co-grazers were included in the study. 
Information about diet was collected retrospectively from the clinical records of hospital-
ized animals.  
A fresh fecal sample was obtained from each horse involved in the study. Sick horses 
were sampled at the time of admission to the clinic. Co-grazers were sampled at home, 
within 24 h since the first affected horse in the pasture showed clinical signs of AM. The 
24 h limit was set in order to avoid the potential effect of management changes (i.e., die-
tary changes, being retired from pasture) implemented by the owner after confirmation 
of AM diagnosis to prevent disease in co-grazers. Fecal samples were collected in all cases 
directly from the rectal ampulla or from a pile of recently passed feces (< 30min). The core 
of a fecal ball was sampled in order to avoid external bacterial contamination [27] and 
immediately placed in a conservation milieu (Stool DNA stabilizer, PSP® Spin Stool DNA 
Plus Kit 00310, Invitek, Berlin, Germany) and stored at −20 °C until total bacterial DNA 
extraction.  
2.2. Inclusion Criteria and Group Definition 
Three separate groups were defined for the purpose of this study, referred to as atyp-
ical myopathy non-survivors (AM-NS), atypical myopathy survivors (AM-S) and healthy 
co-grazers (CG). 
Diagnosis of AM was made based on:  
• a tentative diagnosis of AM based on the algorithm proposed by van Galen et al. 
(2012) [7], i.e., a compatible history (non-exercise-induced acute rhabdomyolysis syn-
drome in a horse kept at pasture) and clinical signs highly suggestive of AM (i.e., 
acute onset of muscle weakness, stiffness and/or pigmenturia) during spring/au-
tumn,  
• elevated serum creatinine kinase activity, presence of HGA and MCPA-carnitine in 
serum and/or modified acylcarnitine profile compatible with the diagnosis of AM, 
when available [28,29]. 
Survivors were discharged from the clinic after a variable hospitalization period, 
whereas non-survivors died naturally from the disease during hospitalization or had to 
be euthanized due to significant clinical deterioration, continuous or unmanageable pain, 
prognostic or economic reasons.  
For the purpose of this study, a healthy co-grazer was defined as a horse: 
• grazing in a pasture where a case of AM had been diagnosed in the previous 24 h. 
• having a normal clinical and dynamic examination at walk (no signs of AM or other 
obvious disease) at the time of sampling. 
2.3. Bacterial DNA Extraction and High-Throughput Sequencing 
Total bacterial DNA was extracted from the stool samples with the PSP Spin Stool 
DNA Plus Kit 00310 (Invitek, Berlin, Germany), following the manufacturer’s recommen-
dations.  
PCR amplification of the 16S rDNA V1–V3 hypervariable region and library prepa-
ration were performed with the following primers (with Illumina overhand adapters), 
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forward (50-GAGAGTTTGATYMTGGCTCAG-30) and reverse (50-AC-
CGCGGCTGCTGGCAC-30). Each PCR product was purified with the Agencourt AM-
Pure XP bead kit (Beckman Coulter, Pasadena, CA, USA) and submitted to a second PCR 
round for indexing, using Nextera XT index primers 1 and 2. After purification, PCR prod-
ucts were quantified using the Quant-IT PicoGreen (ThermoFisher Scientific; Waltham, 
MA, USA) and diluted to 10 ng/µL. A final quantification of each library was performed 
using the KAPA SYBR® FAST qPCR Kit (KapaBiosystems; Wilmington, MA, USA) before 
normalization, pooling and sequencing on a MiSeq sequencer using V3 reagents (Illu-
mina; San Diego, CA, USA). Positive controls using DNA from 20 defined bacterial species 
and negative controls (from extraction and PCR steps) were included in the sequencing 
run [30]. 
Raw amplicon sequencing libraries were submitted to the NCBI database under bi-
oproject number PRJNA682516. 
2.4. Sequence Analysis and 16S rDNA Profiling 
Sequence read processing was performed as previously described [30] using the 
MOTHUR software package v141.1 [31] and VSEARCH algorithm for chimera detection 
[32]. A clustering distance of 0.03 was used for operational taxonomic unit (OTU) genera-
tion. 16S reference alignment and taxonomical assignment from phylum to genus were 
done with MOTHUR and were based upon the SILVA database (v1.32) of full-length 16S 
rDNA sequences [33]. 
Subsample datasets with 8994 cleaned reads per sample were obtained and used to 
evaluate ecological indicators (Good’s coverage, Chao richness index, reciprocal Simpson 
microbial diversity, and Simpson derived evenness of the samples) and β-diversity (using 
a distance Bray–Curtis dissimilarity matrix) using MOTHUR. When assessing the ecology 
of a community (e.g., microbial), α-diversity measures the diversity within the community 
as opposed to β-diversity which measures diversity between communities (or the same 
community at different time points) [34]. Richness is a measure of the number of species 
in the community and evenness expresses how evenly the individuals in the community 
are distributed over the different species (e.g., presence of predominant species) [35]. The 
Good’s coverage estimates what percentage of the total species of a community is repre-
sented in a sample. 
2.5. Data Analysis  
Differences between groups (AM-NS, AM-S, CG) for the different ecological indices 
of the microbial population were assessed with a non-parametric Kruskal–Wallis test fol-
lowed by paired post hoc tests corrected with a two-stage linear step-up procedure of 
Benjamini, Krieger and Yekutieli using PRISM 7 (Graphpad Software; San Diego, CA, 
USA). Differences were considered significant for a q-Value or a p-Value < 0.05. 
β-diversity was visualized with a Bray–Curtis dissimilarity matrix-based non-para-
metric dimensional scaling (NMDS) model using vegan (https://cran.r-pro-
ject.org/web/packages/vegan/index.html) and vegan3d packages (https://cran.r-
project.org/web/packages/vegan3d/index.html) in R. Sample clustering and beta-disper-
sion were respectively assessed in a Bray–Curtis dissimilarity matrix with analysis of mo-
lecular variance (AMOVA) and homogeneity of molecular variance (HOMOVA) tests us-
ing MOTHUR (using 10,000 iterations on the subsampled table). AMOVA determines 
whether the genetic diversity within two or more communities is greater than their pooled 
genetic diversity, and HOMOVA determines whether the amount of genetic diversity in 
each community is significantly different [36].  
Finally, significant differential bacterial population abundance between groups was 
performed with two-way ANOVA with a Benjamini–Hochberg false discovery rate cor-
rection using the population subsampled table where null median populations were re-
moved. 
  





A total of 85 horses were included in the study. These included 59 horses diagnosed 
with AM, of which 29 were survivors (AM-S) and 30 were non-survivors (AM-NS), and 
26 co-grazers (CG). 
The AM-S group included 13 mares, 10 geldings and 6 stallions of a wide variety of 
breeds (7 Warmbloods, 4 ponies, 3 Haflingers, 3 Arabians, 2 Standardbreds and 10 horses 
from other breeds) with a median age of 6.9 years (range 0.4 to 25 years).  
The AM-NS group included 13 mares, 13 geldings and 4 stallions of different breeds 
(including 10 Warmbloods, 5 ponies, 2 Andalusians, 2 Friesians and 11 horses from other 
breeds) with a median age of 7.5 years (range 0.5 to 22 years). From the 30 non-survivors, 
6 died naturally from the disease and 23 were euthanized. Information about the cause of 
death was missing for one horse.  
Concurrently, feces of 26 co-grazers were collected. The co-grazer group included 9 
mares, 4 geldings and one stallion. Different breeds were represented, including 4 Arabi-
ans, 4 Warmbloods, 3 ponies and 11 horses from other breeds. The median age of this 
group was 8.1 years (range 0.6 to 25 years).  
Diet 
All horses included in the present study had access to pasture, including 35 horses 
that were living 24 h a day on pasture. Twenty-one horses (14 AM-NS, 7 AM-S) were 
eating 100% roughage (pasture with or without hay supplement), whereas 11 received 
some kind of sweet feed supplement on top of roughage or pasture (6 AM-NS, 4 AM-S 
and 1 CG). Unfortunately, information about diet was unavailable or poorly specified (i.e., 
lacking amount or type of hay or sweet feed) for 53 of the 85 horses included in this study 
(10 AM-NS, 18 AM-S and 25 CG). 
3.2. Analysis of Microbial Population 
From 12,025,466 raw sequencing reads, 10,225,098 and 8,353,193 reads were obtained, 
respectively, after the cleaning process and chimera removal, with a final median read 
length of 492 nucleotides. Eight thousand nine hundred and ninety-four reads per sample 
were retained as a subsampling process to proceed with OTU binning (0.03 cut-off) for a 
total of 23,406 OTUs regrouped into 583 populations at the genus level. Mean Good’s cov-
erage at the genus level was 99.6%, with no statistical difference between groups. 
3.3. α-Diversity and β-Diversity Analysis 
Microbial population ecological indices of fecal samples were assessed at the genus 
level and are shown in Figure 1. 
Results of the Kruskal–Wallis test yielded significant global differences between 
groups for bacterial alpha-diversity and evenness but not for richness, meaning that the 
number of bacterial genera present in the feces was not significantly different between 
groups. 
According to results of the paired post hoc test, diversity was significantly higher in 
horses with AM (survivors and non-survivors) than in CG (q-Value < 0.001). No significant 
differences were found between survivors and non-survivors (q-Value = 0.969). 
Similarly, genus evenness was found to be significantly higher in horses with AM (sur-
vivors and non-survivors) than in CG (q-Value < 0.0001). This means that the distribution of 
bacterial genera (relative abundance) in the feces of horses with AM is more uniform than 
in the feces of CG, where there is a more marked predominance of certain genera. No sig-
nificant differences were found between survivors and non-survivors (q-Value = 0.616). 




Figure 1. Bacterial intrinsic diversity deduced from inverse Simpson index (A). Bacterial genus richness deduced from 
Chao1 index (B). Bacterial genus evenness deduced from Simpson index (C). Data are scatter dot plots at the genus level 
for individual horses in the three defined groups with the mean and standard deviation. Data with different superscript 
letters are significantly different at q < 0.05 (Kruskal–Wallis). 
β-diversity of the fecal microbial profile was visualized using an NMDS model (three 
dimensions, stress 0.092) (Figure 2). Group clustering testing (AMOVA) revealed signifi-
cant differences between CG and horses diagnosed with AM (p-Value < 0.00001). No sig-
nificant differences were found between survivors and non-survivors (p-Value = 0.2074). 
HOMOVA testing yielded significant results, indicating that the amount of population 
homogeneity in the fecal microbiota was significantly different between CG and horses 
diagnosed with AM (CG vs. AM-S p-Value < 0.00002, CG vs. AM-NS p-Value = 0.0001). 
No significant differences were found between survivors and non-survivors (p-Value = 
0.8098). 




Figure 2. Nonmetric dimensional scaling with three axes of the three horses groups (co-grazers: 
CG, atypical myopathy Scheme 0. 
3.4. Composition of Fecal Microbiota 
A total of 13 different phyla were identified in the feces, the most abundant being 
Firmicutes and Bacteroidetes. The distribution of the main families and genera and their 
relative abundance in the three groups of horses is depicted in Figure 3. 
At a family level, the most abundant families observed were Ruminococcaceae, Lach-
nospiraceae, Clostridiales_fa, Bacteria_fa, Bacteroidales_fa, Rikenellaceae, Christensenel-
laceae, WCHB1-41_fa, Prevotellaceae and p251-o5. 
At a genus level, the most abundant defined genera observed were Lachnospi-
raceae_ge, Ruminococcaceae_ge, Clostridiales_ge, Bacteria_ge, Bacteroidales_ge, Rikenel-
laceae_RC9_gut_group, Ruminococcaceae_UCG-010, Christensenellaceae_R-7_group, WCHB1-
41_ge, Ruminococcaceae_NK4A214_group, p-251-o5_ge and Ruminococcus_1. 




Figure 3. Changes in bacterial populations in the fecal content, assessed by 16S V1-V3 profiling. The bar chart depicts the 
relative abundance of the bacterial families (A) and bacterial genera (B) accounting for more than 1% of the total abun-
dance in the feces. Co-grazers (CG) were compared to horses diagnosed with atypical myopathy (AM) with different 
outcomes (survivors, S, and non-survivors, NS). 
3.5. Statistical Differences in Fecal Microbiota Composition 
According to global ANOVA results, the relative abundance of eight families differed 
significantly between horses diagnosed with AM compared to CG: Ruminococcaceae (p < 
0.0001), Lachnospiraceae (p = 0.0053), Clostridiales_fa (p = 0.0402), Bacteroidales_fa (p < 
0.0001), Rikenellaceae (p = 0.0062), Christensenellaceae (p < 0.0001), p-251-o5 (p = 0.0203) 
and Akkermansiaceae (p = 0.0016). A comparison of the relative abundance of these fam-
ilies between the different groups is shown in Figure 4 and Table 1. 
Relative abundances of Ruminococcaceae, Lachnospiraceae, Bacteroidales_fa Clos-
tridiales_fa, Christensenellaceae and Akkermansiaceae were significantly different be-
tween CG and horses diagnosed with AM, as well as between AM survivors and non-
survivors (p < 0.05 for all comparisons). Interestingly, the relative abundance of each fam-
ily increased (Ruminococcaceae, Christensenellaceae, Akkermansiaceae) or decreased 
(Lachnospiraceae, Bacteroidales_fa, Clostridiales_fa) gradually from CG to non-surviving 
horses suffering from AM (Figure 4). 
Relative abundances of Rikenellaceae and p-251-o5 were lower in CG compared to 
horses diagnosed with AM (q-Value < 0.0001), but no differences were found between AM 
survivors and non-survivors. Rikenellaceae were less abundant in CG compared to horses 
with AM (p < 0.0001), whereas p-251-o5 were more abundant in CG compared to horses 
with AM (p < 0.0001). 




Figure 4. Changes in bacterial family populations in the feces, assessed by 16S V1-V3 profiling and 
expressed as relative population abundance. Bar plot shows mean value with standard deviation 
of selected families whose relative abundance is significantly different between the groups (two-
way ANOVA with Benjamini–Hochberg false discovery rate correction). Data with different su-
perscript letters are significantly different at q < 0.05. Corresponding global p-Values and q-Values 
can be found in Table 1. CG: Co-grazers, AM-S: Atypical myopathy survivors, AM-NS: Atypical 
myopathy non-survivors. 
Table 1. q-Values corresponding to comparisons between groups (two-way ANOVA with Benja-
mini–Hochberg false discovery rate correction) of the eight families depicted in Figure 4. CG: Co-
grazers, AM-S: Atypical myopathy survivors, AM-NS: Atypical myopathy non-survivors. 








Ruminococcaceae <0.0001 <0.0001 <0.0001 <0.0001 
Lachnospiraceae 0.0053 <0.0001 <0.0001 <0.0001 
Bacteroidales_fa <0.0001 <0.0001 <0.0001 <0.0001 
Clostridiales_fa 0.0402 <0.0001 <0.0001 0.0331 
Rikenellaceae 0.0062 <0.0001 <0.0001 0.2263 
Christensenellaceae <0.0001 <0.0001 <0.0001 0.0176 
p-251-o5 0.0203 <0.0001 <0.0001 0.2147 
Akkermansiaceae 0.0016 0.0067 <0.0001 0.0249 
Bold values represent q-Value < 0.05. 
At a genus level, ANOVA global results showed that the relative abundance of 11 
genera differed significantly between horses diagnosed with AM compared to those of 
the CG group: Lachnospiraceae_ge (p = 0.0009), Bacteroidales_ge (p = 0.0001), Christensenel-
laceae_R-7_group (p = 0.0002), Ruminococcaceae_NK4A214_group (p < 0.0001), Ruminococ-
cus_1 (p = 0.0080), Akkermansia (p = 0.0017), Ruminococcaceae_UCG-002 (p = 0.0010), Rikenel-
laceae_RC9_gut_group (p = 0.0075), Ruminococcaceae_UCG-010 (p = 0.0011), p-251-o5_ge (p = 
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0.0278), Bacteroidia_ge (p = 0.0026). A comparison of the relative abundance of these genera 
between the different groups is shown in Figure S1 and Table S1 (Supplementary Data). 
Relative abundances of Lachnospiraceae_ge and Bacteroidales_ge were higher in CG 
compared to diseased horses, whereas Christensenellaceae_R-7_group, Ruminococca-
ceae_NK4A214_group, Ruminococcus_1, Akkermansia and Ruminococcaceae_UCG-002 were 
lower in CG than in horses diagnosed with AM (p < 0.05 for all comparisons). Relative 
abundances of Lachnospiraceae_ge, Bacteroidales_ge and Ruminococcus_1 were higher in AM-
S compared to AM-NS, whereas Christensenellaceae_R-7_group, Ruminococca-
ceae_NK4A214_group, Akkermansia and Ruminococcaceae_UCG-002 were lower in AM sur-
vivors compared to non-survivors (p < 0.05 for all comparisons). Similarly to results at the 
family level, the relative abundance of most of those genera increased (Christensenel-
laceae_R-7_group, Ruminococcaceae_NK4A214_group, Akkermansia and Ruminococca-
ceae_UCG-002) or decreased (Lachnospiraceae_ge, Bacteroidales_ge) gradually from CG to 
non-surviving horses suffering from AM (Figure S1 in Supplementary Data). 
Relative abundances of Rikenellaceae_RC9_gut_grou, Ruminococcaceae_UCG-010 and p-
251-o5_ge were significantly different between CG and horses diagnosed with AM (p < 
0.05 for all comparisons), but no differences were found between AM survivors and non-
survivors. Rikenellaceae_RC9_gut_grou and Ruminococcaceae_UCG-010 were significantly 
less abundant in CG in regard to horses with AM, whereas p-251-o5_ge were significantly 
more abundant in CG in regard to horses with AM (p < 0.05 for all comparisons). 
4. Discussion 
This study demonstrates significant differences in the structure and composition of 
fecal microbiota in horses with AM in regard to their healthy co-grazers. Diversity was 
significantly higher in horses with AM (survivors and non-survivors) and relative abun-
dances of certain bacterial families were significantly higher (Ruminococcaceae, Chris-
tensenellaceae, Rikenellaceae and Akkermansiaceae) or lower (Lachnospiraceae, Clostrid-
iales_fa, Bacteroidales_fa, p-251-o5) than in co-grazers. Interestingly, most of these bacte-
rial shifts were significantly more pronounced in non-survivors. 
When interpreting microbiome changes associated with a specific disease, two hy-
potheses arise: changes can be either a trigger or a consequence of the disease. A specific 
microbiome (or its metabolome) can be a predisposing/protecting factor for the disease, 
providing each individual with a major or minor susceptibility to the disease. On the other 
hand, the disease process itself can induce more or less profound changes in the microbi-
ome of an individual. Untangling the cause–consequence relationship between the intes-
tinal microbiome and AM in horses might aid in developing therapeutic and/or preven-
tive strategies for at-risk horses. 
4.1. Differences in Community Structure between CG and Horses with AM 
Fecal bacterial richness did not appear to be affected by clinical disease in the present 
study, but diversity and evenness were significantly higher in horses with AM than in 
CG. 
Diseases characterized by bacterial dysbiosis in horses, such as colitis, have been as-
sociated with lower diversity, lower richness and lower evenness in fecal microbiota in 
regard to healthy horses [37,38]. Changes in fecal bacterial diversity have also been ob-
served to be associated with other equine disorders, such as equine metabolic syndrome 
(EMS). Horses with EMS showed lower fecal microbial diversity when compared to con-
trols in one study [19], whereas horses suffering from naturally occurring chronic lamini-
tis showed higher fecal microbial diversity compared to non-laminitic control horses [39]. 
In vitro and in vivo studies have demonstrated a causative link of carbohydrate-induced 
laminitis and alterations in the gut microbiome [18,40–42], however, the relevance of fecal 
bacterial diversity changes concerning horses with EMS or AM remains to be determined. 
Similarly to humans [43], one study reported a reduction in fecal microbial diversity 
in aged animals (19 to 25 years old) in regard to adult horses (5 to 12 years old), although 
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no significant differences in specific bacterial populations were found [44]. In the present 
study, the median and range of age of the three groups of horses compared were quite 
similar, so a bias of age affecting the results is unlikely. 
Taking into account that horses diagnosed with AM were treated in referral hospi-
tals, and most co-grazers were sampled at the barn, transport to the hospital could have 
interfered with disease-associated results. A recent study found that transportation of 
healthy horses to a hospital facility resulted in an increase in richness and Shannon diver-
sity index which normalized within 24 h [45]. On the contrary, a previous study did not 
find any effect of transport on alpha-diversity indices in adult horses after 1h of transport 
(richness, diversity, evenness) [46]. In the present study, the vast majority of diseased 
horses had a transport time to the hospital ranging from 30 min to 2 h. 
This is, to our knowledge, the first study assessing microbiota in horses with AM 
[7,47]. The interpretation of increased diversity and evenness in the AM group is not clear 
to date. The effect of HGA or MCPG on fecal microbiota has never been studied in the 
equine species, so it remains unknown if protoxins (or their toxic metabolites) could alter 
the structure or composition of fecal microbiota in horses ingesting them.  
4.2. Differences in Community Composition Between CG and Horses with AM 
The predominant phyla in the three groups of this study were Firmicutes and Bac-
teroidetes. Bacterial shifts observed between horses suffering from AM and healthy co-
grazers affected mainly families and genera included in the core equine intestinal micro-
biota [17,48–50]. The term “core microbiota” refers to the key bacterial populations which 
are present in most individuals, probably playing essential roles and defining what is con-
sidered as a “healthy microbiota” [51]. 
Lachnospiraceae and Ruminococcaceae are members of the Firmicutes phylum and 
constitute two of the main families of active bacteria present in the distal gut of both hu-
mans and horses [52,53]. Both families play important roles in gastrointestinal health: they 
are cellulolytic, fibrolytic bacteria, and major producers of short-chain fatty acids [51]. 
Some of the species in these families produce butyrate, which has been related to a healthy 
colonic mucosa [54]. Several studies have shown consistently lower relative abundances 
of Lachnospiraceae and Ruminococcaceae families in humans and animals with gastroin-
testinal disease [13,17,37]. 
Evidence in human and equine medicine shows that diet, particularly dietary carbo-
hydrates, can influence the composition and stability of the gut microbiome [44,55–58]. A 
study found that the relative abundances of Lachnospiraceae and Bacteroidetes were sig-
nificantly greater and Ruminococcaceae significantly lower in concentrate-fed horses 
compared with grass-fed horses [59]. All horses included in the present study had access 
to pasture, including 35 horses that were living 24 h a day on pasture. Twenty-one horses 
were eating 100% roughage (pasture with or without hay supplement), whereas 11 re-
ceived some kind of sweet feed supplement on top of roughage or pasture. Unfortunately, 
information about diet was unavailable or poorly specified (i.e., lacking amount or type 
of hay or sweet feed) for 53 of the 85 horses included in this study, which makes it difficult 
to interpret and discuss the results in relation to diet. However, as the CG horses were 
kept on the same pastures as the AM-affected horses, they most likely received the same 
diet as the diseased horses, as grazing horses are very rarely fed individually. 
The Lachnospiraceae family is the main component of a select core bacterial commu-
nity which is found in all horses regardless of age or diet, and some authors suggest that 
it could explain why horses are especially susceptible to metabolic dysfunction [44]. Mem-
bers of this family seem to play a protective role against disease in humans and animals. 
It has been suggested that the indigenous microbiota could inhibit the colonization of 
pathogenic bacteria by several mechanisms, including the production of metabolites such 
as short-chain fatty acids, bacteriocins or other antimicrobial compounds, as well as com-
peting for limiting nutrients (nutrient niche hypothesis) [60]. Many members of the family 
Lachnospiraceae are relevant for the growth of other microbes and host epithelial cells 
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due to their production of butyric acid. Based on this ability, Lachnospiraceae have been 
associated with protection from colon cancer in humans by activating the activating pro-
tein 1 (AP-1) signaling pathway in human epithelial cells [61–63]. This pathway, among 
others, is involved in cellular growth control, and therefore regulates cell life or death in 
connection with extracellular stimuli [64]. If the same mechanism happens in equine in-
testinal epithelial cells, a decrease in Lachnospiraceae might impact their proliferation and 
likely affect the mucosal barrier function, making it easier for undesired gut contents, like 
toxins, to trespass into the circulation. However, more studies are needed to confirm this 
link, especially in horses. As horses with AM seem to have a decrease in the relative abun-
dance of Lachnospiraceae, it can be hypothesized that the aforementioned protective roles 
of this family are diminished in horses suffering from the disease, which could potentially 
favor disease progress. Further investigation of this link might aid in discovering preven-
tative or treatment strategies against AM. 
The family Christensenellaceae, within the bacterial phylum Firmicutes, has gained 
increasing recognition in recent years due to its strong link to human body condition (BC), 
as shown in multiple studies investigating different populations. An inverse relationship 
between host body mass index (BMI) and the relative abundance of Christenellaceae has 
been demonstrated in humans, and an adaptation of the relative abundance of this family 
has been observed in fecal microbiota when obese individuals are losing weight [65–67]. 
Interestingly, a previous study demonstrated that lean horses were more prone to devel-
oping clinical signs of AM [3]. However, to the authors’ knowledge, a correlation between 
BC and the relative abundance of Christenellaceae has not yet been demonstrated in 
horses, but it could be interesting to evaluate. Body condition was not adequately refer-
enced for all horses included in this study but available information from hospital files 
revealed an average BC for most diseased horses (4–5/9 Henneke BC score), with no cases 
of extreme obesity or emaciation. 
Evidence concerning the relation between the microbiota composition and BC in 
horses is conflicting to date [44,68,69]. Similarly to the present results, a study in horses 
with EMS found an increase in the family Akkermansiaceae (phylum Verrucomicrobia) 
in regard to control horses [19]. The genus Akkermansia, a group of mucolytic mucosa-
associated bacteria, has received special attention in the literature as a biomarker for a 
healthy intestine as its relative abundance is inversely correlated to human intestinal dis-
ease, such as inflammatory bowel disease, Crohn’s disease, ulcerative colitis and appen-
dicitis, but also extra-intestinal issues such as obesity and autism in children [70–75]. In-
terestingly, those bacteria seem to thrive following decreased intestinal nutrient availabil-
ity, as seen in intestinal contents of human patients after gastric bypass surgery or the 
cecum of hamsters that are fasted [73,76]. Oral administration of Akkermansia spp. has been 
shown to improve glucose tolerance in obese mice [77]. Such effects could be interesting 
in a situation of impaired lipid metabolism but preserved glycolytic pathways, as is the 
case for AM-affected horses [78]. 
Whether these bacterial shifts observed in horses with AM when compared to co-
grazers are a consequence of the intoxication or occurred prior to ingestion of the protoxin 
remains to be determined. Prospective studies following exposure to the toxin and its con-
sequences on fecal microbiota in horses grazing in at-risk pastures could help to answer 
that question. 
4.3. Association with Outcome in Horses with AM 
Most bacterial shifts observed in this study between horses suffering from AM and 
healthy co-grazers were significantly more pronounced in non-survivors than in survi-
vors. This gradual increase/decrease in certain bacterial populations in the feces of horses 
with AM associated with severity of the disease could suggest a dysbiosis that worsens as 
the disease progresses. The significance of this finding is unclear, and the nature of this 
correlation remains to be determined. but may be related to the amount of toxin ingested, 
which could be higher in non-survivors. Because the study was conducted in naturally 
Animals 2021, 11, 506 13 of 17 
 
 
occurring cases of AM, the exact amount of HGA and MCPG ingested by each horse re-
mains undetermined, and this factor might have influenced morbidity and mortality. 
However, the serum acylcarnitine profile (Table S2) of non-surviving horses in this study 
showed more severe changes than in survivors, suggesting worse metabolic imbalances 
in horses with a poor outcome. The serum acylcarnitine profile has been shown to be a 
good predictor for survival in horses with AM [29]. 
Considering the potential of some bacteria to metabolize amino acids, another hy-
pothesis could be that intestinal microbiota might contribute to the conversion of HGA 
into MCPA-CoA, accelerating the intoxication process. A wide range of bacteria, includ-
ing the genera Fusobacterium, Bacteroides, Propionibacterium, Actinomyces, Peptococcus, Strep-
tococcus, Ruminococcus, Megasphaera and even Enterobacteria (Escherichia coli, Klebsiella sp., 
Streptococcus sp.), have been reported as being responsible for amino acid metabolism in 
the gut [24,79]. Whether the significantly increased relative abundance of Ruminococca-
ceae observed in this study in horses suffering from AM is related to this latter hypothesis 
remains to be determined and deserves further study. 
4.4. Limitations 
This study has certain limitations. Single samples, in general, provide more limited 
information than a multiple sample follow-up. The results are based on fecal microbiota, 
which is acceptable to represent the distal part of the equine digestive system, but cannot 
be used to predict microbiota of the proximal digestive tract [48,80]. Whether the micro-
biota of the proximal intestinal tract is altered in horses with AM and how this affects 
progression of the disease remain to be studied. Furthermore, only the bacterial popula-
tions in the feces were analyzed, leaving out the small but significant groups of eukary-
otes, archaea, viruses and fungi that are equally present in the gastrointestinal tract [81]. 
Dietary management is known to affect the composition of fecal microbiota and diet 
was not homogeneous in this study (i.e., some horses received sweet feed supplement 
whereas other received only roughage). Unfortunately, a lot of detail on dietary data was 
missing, which made it difficult to analyze, interpret and discuss the results in regard to 
diet groups. It should be noted that not all horses included in the study had a correspond-
ing co-grazer in the CG group. Some horses were living alone and no companions were 
available, sometimes all horses in the same pasture were sick or management of co-grazers 
from a sick case had already been modified by the owner (e.g., removal from pasture, 
dietary supplementation) before the 24 h window. 
Some of the horses in our study were humanely euthanized rather than dying natu-
rally from the disease, which might have created a bias in the AM-NS group and therefore 
influenced our results regarding disease outcome. On the other hand, the severity of clin-
ical signs in horses that were euthanized was clearly more pronounced compared to clin-
ical signs of survivors, which in most cases ultimately led to the decision to euthanize the 
animal. 
Finally, diseased horses included in this study were referred cases and sometimes 
the field practitioner had administered some medication prior to referral (i.e., charcoal or 
paraffin oil, non-steroidal anti-inflammatory drugs and/or vitamins) which could have 
influenced the results of this study. Fecal sampling in sick horses was performed on ad-
mission to the hospital, and in most cases within the first 24 h of clinical manifestation of 
the disease. In consequence, it seems very unlikely that any treatment administered by 
the veterinarian may have influenced the composition of fecal microbiota in these horses. 
5. Conclusions 
This study demonstrates significant differences in the structure and composition of 
the fecal microbiota of AM-affected horses when compared to their non-affected co-graz-
ers. The families Ruminococcaceae, Christensenellaceae and Akkermansiaceae increased, 
whereas the Lachnospiraceae, Bacteroidales and Clostridiales decreased in horses with 
AM, especially in those with a poor prognosis. Further studies are needed to determine if 
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those changes precede the disease or are a consequence of the intoxication. Either way, 
the findings of this study constitute a first step in understanding the possible role of in-
testinal microbiota in AM and may open new fields for the prevention and treatment of 
this devastating disease. 
Supplementary Materials: The following are available online at www.mdpi.com/2076-
2615/11/2/506/s1. Figure S1: Changes in bacterial genus populations in the feces assessed by 16S V1-
V3 profiling and expressed as relative population abundance, Table S1: q-Values corresponding to 
comparisons between groups (two-way ANOVA with Benjamini–Hochberg false discovery rate cor-
rection) of the 11 genera depicted in Figure S1. Table S2: Serum acylcarnitine concentrations from 
horses with AM included in this study. 
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